



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

American Journal of Otolaryngology–Head and Neck Medicine and Surgery

journal homepage: www.elsevier.com/locate/amjoto

How does Covid-19 infection affect smell?

ARTICLE INFO

Keywords

Covid-19
Smell loss, hyposmia, stem cells, nasal mucus,
theophylline
Metabolic disorder

Loss of smell is a common sequela after a patient experiences Covid-19 infection; as many as 68% of patients who experience Covid-19 infection have loss of smell [1]. While this symptom is commonly transient and can occur in absence of any other clinical symptoms many patients develop a chronic loss of smell. How does this occur?

Loss of smell following a viral infection was first described clinically in 1975 [2]. After a viral infection many patients report a chronic loss of smell. Indeed this patient group represents the majority among several pathological entities that cause smell loss accounting for about 25% of all patients who reported smell loss [3]. However, the type of virus which caused the smell loss was not previously determined nor was the mechanism which caused this loss [2]. In order to understand this symptom and how it is related to Covid-19 infection, a systematic evaluation of this sensory system was explored.

The smell system is comprised of three major components – brain, nerves and receptors. Although each portion of this system can exhibit pathology which can inhibit smell, the major component through which pathology occurs is through pathogenesis in the olfactory receptors. Olfactory receptors are unique since they do not contain blood vessels, lymphatics or exhibit mitosis [4]. These receptors, which turn over frequently, as often as every 24 h, depend upon stem cells which respond to growth or transcription factors secreted into nasal mucus from nasal serous glands [5]. These growth factors then activate stem cells to mature and generate the olfactory receptors by which the smell response is initiated [5]. Indeed, nasal mucus secreted from serous glands in the nasal cavity is the critical fluid through which these receptors grow and mature to maintain smell function. Indeed, failure to produce nasal mucus or salivary secretions (saliva), as occurs in Sjogren's syndrome, causes loss of sensory receptors with subsequent loss of smell and taste [6]. Restoration of these secretions is associated with the restoration of the sensory receptors and subsequent return of sensory function.

In order to understand the nature of these nasal mucus growth factors a total protein analysis of the components of nasal mucus was undertaken [7]. This analysis demonstrated the presence of several moieties which can be considered as the growth factors that stimulate these stem cells. These moieties include cyclic AMP and cGMP [8] and sonic hedgehog [9]. Inhibition of secretion of these growth factors is associated with inhibition of stem cell activity with subsequent

inhibition of stimulation of olfactory receptor cells [5] and subsequent loss of smell. While the immune and other systems may eventually inhibit the general viremia associated with Covid-19 infection, the Covid-19 virus attacks the nasal serous glands directly and inhibits secretion of these growth factors which are necessary for stem cell activation.

Since these olfactory receptors turn over rapidly [4], they require continued stimulation by these growth factors. If this stimulation is inhibited these receptors do not grow or mature leading to smell loss. Even transient inhibition of these growth factors causes inhibition of receptor development with subsequent loss of smell. This common transient loss of growth-factor secretion may relate to the transient loss of smell observed in many patients after Covid-19 infection. Persistent secretion loss causes continued inhibition of stem cell activity with resulting loss of receptor growth with persistent loss of smell.

Other studies have considered that neural factors involving the brain and the olfactory neurons themselves are responsible for the smell loss following Covid-19 infection [10]. In a recent report specific insight into the mechanism of the loss suggested that smell loss was mediated by transient dysfunction of the olfactory epithelium [11]. This observation is consistent with the mechanism presented in the present formulation.

Studies in other hyposmic patients indicate that restoration of secretion of these affected growth factors is associated with restoration of stem cell activation, olfactory receptor growth and development, and return of smell function [12]. This stimulation occurs by two mutually dependent mechanisms – the action of cAMP, cGMP [7] and sonic hedgehog [8] on olfactory receptor function, and direct stimulation of stem cells which initiate growth of these sensory receptors [12]. The present formulation of transient smell loss is more consistent with a metabolic rather than a direct neural cause of smell loss after Covid-19 infection. Indeed stimulation of these growth factors in other hyposmic patients, demonstrated by the use of phosphodiesterase inhibition, such as theophylline administration [12], activated nasal mucus cAMP, cGMP [7] and sonic hedgehog secretion [8] which in turn activated smell function.

<https://doi.org/10.1016/j.amjoto.2021.102912>

Received 15 December 2020

Available online 27 January 2021

0196-0709/© 2021 Elsevier Inc. All rights reserved.

References

- [1] Gandhi, Rajesh T., Lynch, John B, del io, Carlos. Mild or moderate Covid-19. *N Engl J Med* 2020;383:1757–66.
- [2] Henkin RI, Larson AL, Powell RD. Hypogeusia, dysgeusia, hyposmia and dysosmia following influenza-like infection. *Ann Otol Rhin Laryngol* 1975;84:672–82.
- [3] Henkin RI, Levy LM, Fordyce A. Taste and smell function in chronic disease: a review of clinical and biochemical evaluation of taste and smell dysfunction in over 5000 patients at The Taste and Smell Clinic in Washington. DC *AM J Otolaryngol* 2013;34:477–89.
- [4] Henkin RI. Evaluation and treatment of human olfactory dysfunction. In: English GM, editor. *Otolaryngology*. 2. Philadelphia: Lippincott; 1993. p. 1–86.
- [5] Henkin RI. Growth factors in olfaction. In: Preedy VR, editor. *The handbook of growth and growth monitoring in health and disease*. II. New York: Springer-Verlag; 2011. p. 1217–436.
- [6] Henkin RI, Talal N, Larson AL, Mattern CF. Abnormalities of taste and smell in Sjogren's syndrome. *Ann Intern Med* 1972;76:375–83.
- [7] Henkin RI, Doherty AE, Martin BM. Nasal seroproteins: A new frontier in the exploration of physiology and pathology of nasal and sinus disease. In: Veldman JE, Passali D, Lim DJ, editors. *New frontiers in immunobiology*. The Hague: Kugler; 2000. p. 127–52.
- [8] Henkin RI, Velicu I, Papathanassiu A. cAMP and cGMP in human parotid saliva: relationships to taste and smell dysfunction, gender and age. *Am J Med Sci* 2007; 334:431–40.
- [9] Henkin RI, Hoein S, Stateman WA, Knöppel AB. Sonic hedgehog in nasal mucus is a biomarker for smell loss in patients with hyposmia. *Cell Mol Med*. 2016, 2:2 [Open Access Journal].
- [10] Iadecola, Costantino, Anrather, Josef, Kamel, Hooman. Effects of Covid-19 on the nervous system. *Cell*. Vol. 183, Issue 1 October 2020;16–27.
- [11] Singhal Aneesh B, Gonzales R Gilberto, Chwalisz Bart K, Mukerji Shibani S. Case 26-2020: a 60-year-old woman with altered mental status and weakness on the left side. *New Engl J Med* 2020;383:764–73.
- [12] Henkin RI, Abdelmeguid M. Improved smell and taste dysfunction with intranasal theophylline. *Am J Otolaryngol Head Neck Surg* 2019;2(9):1070.

Robert I. Henkin

*The Taste and Smell Clinic, 5125 MacArthur Blvd., N.W., #20,
Washington, DC 20016, United States of America
E-mail address: doc@tasteandsmell.com.*